Bangladesh to send Remdesivir drug, medical supplies to India next week

Bangladesh will be sending Remdesivir, an anti-viral medicine being used in COVID-19 treatment, along with other medical supplies to India next week, said country's Foreign Secretary Masud Bin Momen.

"India sought Remdesivir [from us]. We have taken measures to send it," Dhaka Tribune quoted Momen said on Thursday.

The demand for the drug has recently increased in India, as the country witnessed a sudden rise in coronavirus cases.

The worsening COVID-19 situation has seen a surge in the demand for medical oxygen, drugs and beds for the COVID-19 patients and many states are reporting an acute shortage in essential medical supplies.

Last week, the Indian government waived import duty for the Remdesivir vials and the raw materials.

Bangladesh Foreign Ministry on Wednesday offered to dispatch emergency medicines and medical equipment supplies for the people of India who are fighting against the COVID-19 pandemic.

The supplies include about 10,000 vials of injectable anti-viral, oral anti-viral, 30,000 PPE kits, and several thousand zinc, calcium, vitamin C and other necessary tablets

About the risks of the Indian triple mutant Covid-19 variant entering Bangladesh, the foreign secretary said: "The situation in the country will be manageable if the infection rate goes down."

Bangladesh on April 25 closed its border with India for 14 days to control the spread of the deadly virus.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel